"Moderna's full-year 2025 revenue came in at $1.944 billion, down 39.23% year over year, with a net loss of $2.822 billion and negative free cash flow of $2.065 billion."
"The pipeline is ambitious: a flu-COVID combo vaccine is under EMA review, a personalized cancer vaccine developed with Merck showed a 49% reduction in recurrence or death versus Keytruda alone in melanoma."
"Novavax is the only one of the three currently profitable, with its most recent quarter posting EPS of $0.11, beating estimates of negative $0.42 by 126.15%."
Moderna, BioNTech, and Novavax have seen significant stock declines since the COVID-19 vaccine boom. Moderna's revenue fell 39.23% year-over-year, with a net loss of $2.822 billion. Despite its ambitious pipeline, including a flu-COVID combo vaccine, the company faces challenges with negative earnings per share. Novavax remains profitable, posting an EPS of $0.11, but its growth potential may be limited. Investors are left questioning which company can successfully navigate the post-pandemic landscape and deliver sustainable growth.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]